Company attributes
Other attributes
Abcuro develops immunotherapies for autoimmune diseases and cancer. Abcuro’s foundational IP was developed by Dr. Steven A Greenberg and licensed from Brigham and Women’s Hospital. Abcuro’s immunotherapies function through elimination or modulation of cytotoxic T cells and natural killer (NK) cells via the co-inhibitory receptor killer-cell lectin receptor G1 (KLRG1). KLRG1 is expressed on NK cells and antigen-experienced T cells. In the context of cancer KLRG1 is an immune checkpoint receptor expressed predominantly on late-differentiated effector and effector memory cytotoxic CD8+ T and NK cells.
ABC008 is an immunotherapy candidate at preclinical stage that is an anti-KLRG1 cell depleter which selectively removes pathogenic cytotoxic T cells.
ABC015 is an immunotherapy candidate at preclinical stage that is an anti-KLRG1 cell activator which reactivates inhibited cytotoxic T and NK cells.
